Suppr超能文献

用于解读 [F]PSMA-1007 PET/CT 成像的激素敏感性前列腺癌患者骨局灶性摄取的综合预测评分。

Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [F]PSMA-1007 PET/CT.

机构信息

Department of Health Sciences, University of Genova, Genova, Italy;

Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

出版信息

J Nucl Med. 2024 Oct 1;65(10):1577-1583. doi: 10.2967/jnumed.124.267751.

Abstract

Unspecific bone uptake (UBU) related to [F]PSMA-1007 PET/CT imaging represents a clinical challenge. We aimed to assess whether a combination of clinical, biochemical, and imaging parameters could predict skeletal metastases in patients with [F]PSMA-1007 bone focal uptake, aiding in result interpretation. We retrospectively analyzed [F]PSMA-1007 PET/CT performed in hormone-sensitive prostate cancer (PCa) patients at 3 tertiary-level cancer centers. A fourth center was involved in performing an external validation. For each, a volume of interest was drawn using a threshold method to extract SUV, SUV, PSMA tumor volume, and total lesion PSMA. The same volume of interest was applied to CT images to calculate the mean Hounsfield units (HU) and maximum Hounsfield units. Clinical and laboratory data were collected from electronic medical records. A composite reference standard, including follow-up histopathology, biochemistry, and imaging data, was used to distinguish between PCa bone metastases and UBU. PET readers with less ( = 2) or more ( = 2) experience, masked to the reference standard, were asked to visually rate a subset of focal bone uptake ( = 178) as PCa metastases or not. In total, 448 bone [F]PSMA-1007 focal uptake specimens were identified in 267 PCa patients. Of the 448 uptake samples, 188 (41.9%) corresponded to PCa metastases. Ongoing androgen deprivation therapy at PET/CT ( < 0.001) with determination of SUV ( < 0.001) and HU ( < 0.001) independently predicted bone metastases. A composite prediction score, the bone uptake metastatic probability (BUMP) score, achieving an area under the receiver-operating-characteristic curve (AUC) of 0.87, was validated through a 10-fold internal and external validation ( = 89 bone uptake, 51% metastatic; AUC, 0.92). The BUMP score's AUC was significantly higher than that of HU (AUC, 0.62) and remained high among lesions with HU in the first tertile (AUC, 0.80). A decision-curve analysis showed a higher net benefit with the score. Compared with the visual assessment, the BUMP score provided added value in terms of specificity in less-experienced PET readers (88% vs. 54%, < 0.001). The BUMP score accurately distinguished UBU from bone metastases in PCa patients with [F]PSMA-1007 focal bone uptake at PET imaging, offering additional value compared with the simple assessment of the osteoblastic CT correlate. Its use could help clinicians interpret imaging results, particularly those with less experience, potentially reducing the risk of patient overstaging.

摘要

非特异性骨摄取(UBU)与 [F]PSMA-1007 PET/CT 成像相关,这是一个临床挑战。我们旨在评估在 [F]PSMA-1007 骨局灶性摄取的患者中,结合临床、生化和影像学参数是否可以预测骨转移,以辅助结果解读。

我们回顾性分析了在 3 个三级癌症中心进行的激素敏感前列腺癌(PCa)患者的 [F]PSMA-1007 PET/CT。第四个中心参与了外部验证。对于每个患者,我们使用阈值方法绘制感兴趣区域,以提取 SUV、PSMA 肿瘤体积和总病变 PSMA。相同的感兴趣区域应用于 CT 图像以计算平均亨氏单位(HU)和最大亨氏单位。临床和实验室数据从电子病历中收集。采用包括随访组织病理学、生物化学和影像学数据的综合参考标准,将 PCa 骨转移与 UBU 区分开来。经验较少(=2)或较多(=2)的 PET 读者,对参考标准进行屏蔽,被要求对一组局灶性骨摄取(=178)进行视觉评估,判断其为 PCa 转移或非转移。

总共在 267 例 PCa 患者中发现了 448 个骨 [F]PSMA-1007 局灶性摄取标本。在 448 个摄取样本中,188 个(41.9%)与 PCa 转移相对应。在 PET/CT 时持续进行雄激素剥夺治疗(<0.001),SUV(<0.001)和 HU(<0.001)的测定独立预测了骨转移。复合预测评分,骨摄取转移概率(BUMP)评分,在 10 倍的内部和外部验证中获得了接收器操作特征曲线(ROC)下面积(AUC)为 0.87(=89 个骨摄取,51%转移;AUC,0.92)。BUMP 评分的 AUC 明显高于 HU(AUC,0.62),并且在 HU 处于第一三分位的病变中仍保持较高水平(AUC,0.80)。决策曲线分析显示评分具有更高的净效益。与视觉评估相比,BUMP 评分在经验较少的 PET 读者中提供了更高的特异性(88%比 54%,<0.001)。

BUMP 评分在接受 [F]PSMA-1007 骨局灶性摄取 PET 成像的 PCa 患者中准确地区分了 UBU 与骨转移,与简单评估成骨性 CT 相关性相比提供了额外的价值。它的使用可以帮助临床医生解释成像结果,特别是对于经验较少的医生,可能会降低患者过度分期的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验